PubMed · 2023

Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial

Frias JP, Deenadayalan S, Erichsen L, et al. (2023). Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial. Nat Med.

Nat Med

View original source

Peptides linked in PeptIQ Wiki

CagriSema — community report

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.